Pfizer’s stock price dropped sharply after the company reported lower-than-expected earnings. The pharmaceutical giant missed forecasts due to several acquisitions, including the purchase of Metsera for $10 billion.
Analysts say it’s not a major surprise, as Pfizer had warned about potential dilution from its new acquisitions. The company expects to earn between $2.80 and $3 per share this year, but its earnings fell short of analysts’ expectations.
Pfizer is also facing patent cliffs for some of its biggest-selling products, including Eliquis and Xtandi. This means that generic copies will become available, potentially reducing sales. However, analysts believe that Pfizer’s pipeline of obesity and cancer treatments could offset the impact of the patent cliff.
The company has signed several licensing deals with other companies in the cancer and weight-loss spaces, but these may not be enough to stabilize its earnings. Pfizer’s stock remains above its key moving averages, but fell 3.4% on Tuesday.
Source: https://www.investors.com/news/technology/pfizer-stock-pfizer-guidance-2026